In addition to optimising drug selectivity and dose to enhance efficacy and safety, the control of systemic metabolism by dietary manipulation is shown to be a highly effective strategy for improving safety and efficacy of PI3K inhibitors in preclinical cancer models [19]. The gene discussed is PIK3CG; the disease is cancer.